BeOne Medicines
ONC
#717
Rank
HK$254.62 B
Marketcap
HK$2,217
Share price
2.20%
Change (1 day)
8.56%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeOne Medicines (ONC)

Earnings in 2025 (TTM): HK$3.70 Billion

According to BeOne Medicines's latest financial reports the company's current earnings are HK$5.34 Billion. , an increase over its 2024 earnings that were of -HK$4.46 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeOne Medicines from 2015 to 2025

Annual earnings

Year Earnings Change
2025 HK$3.72 B-183.61%
2024 -HK$4.46 Billion-52.95%
2023 -HK$9.46 Billion-32.52%
2022 -HK$14.02 Billion24.39%
2021 -HK$11.27 Billion-13.21%
2020 -HK$12.99 Billion72.69%
2019 -HK$7.52 Billion36.01%
2018 -HK$5.53 Billion616.83%
2017 -HK$0.78 Billion-15.24%
2016 -HK$0.91 Billion107.91%
2015 -HK$0.44 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
OPKO Health
OPK
-HK$1.25 Billion-133.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-HK$0.15 Billion-103.82%๐Ÿ‡บ๐Ÿ‡ธ USA